Aarvik Therapeutics
Aarvik Therapeutics is advancing biologics to transform cancer treatment by developing molecules with an improved therapeutic index for oncology targets. They combine novel modular antibody platforms with multiple target mechanisms, offering scalable, versatile, and manufacturable antibody platforms with unlimited potential through modular design.
Industries
Nr. of Employees
small (1-50)
Products
Aarvik MUTTA™ ADC Platform
A proprietary antibody-drug conjugate (ADC) platform developed by Aarvik Therapeutics supporting multitarget and multivalent designs up to 4 targets with modular architecture, proprietary hydrophilic cleavable linkers, and site-specific conjugation.
Aarvik MUTTA™ ADC Platform
A proprietary antibody-drug conjugate (ADC) platform developed by Aarvik Therapeutics supporting multitarget and multivalent designs up to 4 targets with modular architecture, proprietary hydrophilic cleavable linkers, and site-specific conjugation.
Services
Joint research collaborations, licensing and option arrangements to apply modular antibody engineering platforms and advance oncology drug candidates.
Joint research collaborations, licensing and option arrangements to apply modular antibody engineering platforms and advance oncology drug candidates.
Expertise Areas
- Antibody engineering
- Antibody–drug conjugate (ADC) development
- Protein engineering and synthetic antibody libraries
- Preclinical development and IND-enabling studies
Key Technologies
- Site-specific antibody conjugation
- Tetravalent and multivalent antibody formats
- Bispecific / T-cell engager formats
- Phage display
News & Updates
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Aarvik Therapeutics Announces a Global Novel Payload Agreement with NJ Bio, Inc.
Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
Aarvik Therapeutics Appoints Dr. Richard Scheller to Board of Directors, Dr. Melissa Starovasnik to Scientific Advisory Board, and Announces Scientific Team
Aarvik Therapeutics (formerly Aarkus Therapeutics) Announces Successful Series Seed Financing
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Aarvik Therapeutics Announces a Global Novel Payload Agreement with NJ Bio, Inc.
Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
Aarvik Therapeutics Appoints Dr. Richard Scheller to Board of Directors, Dr. Melissa Starovasnik to Scientific Advisory Board, and Announces Scientific Team
Aarvik Therapeutics (formerly Aarkus Therapeutics) Announces Successful Series Seed Financing